Search Results - "SIMIONI, P."

The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit by Fabris, L., Campello, E., Cadamuro, M., Simioni, P.

“…Metabolic dysfunction-associated fatty liver disease (MAFLD), the hepatic component of the metabolic syndrome caused by insulin resistance, is a major public…”
Get full text

Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)—rationale and protocol by Camporese, G., Bernardi, E., Bortoluzzi, C., Noventa, F., Simioni, P.

“…No data is available about pharmacological secondary prevention of superficial vein thrombosis (SVT) despite 10–15% of patients develop venous thromboembolic…”
Get full text

I339 SCREENING OF HEMATOLOGIC ABNORMALITIES AND THROMBOPHILIA IN PREGNANCY by Simioni, P.

Get full text

Structural and histochemical attributes of secretory ducts and cavities in leaves of four species of Calophyllaceae J. Agardh in Amazonian savannas by Pessoa, M. J. G., Pireda, S., Simioni, P., Bautz, N., Da Cunha, M., Mock, H.‐P.

“…This study represents an important contribution to the structural, histochemical and biological understanding of ducts and cavities in leaves of four species…”
Get full text

Increased anticoagulant response to low‐molecular‐weight heparin in plasma from patients with advanced cirrhosis by SENZOLO, M., RODRIGUEZ‐Castro, K. I., ROSSETTO, V., RADU, C., GAVASSO, S., CARRARO, P., ZERBINATI, P., SARTORI, M. T., SIMIONI, P.

“…Introduction:  Cirrhotic patients may present thrombotic complications that warrant anticoagulant therapy. However, the efficacy of low‐molecular‐weight…”
Get full text

Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation by Camporese, G., Bernardi, D., Bernardi, E., Avruscio, G.P., Marchini, F., Bonfante, L., Furian, L., Neri, F., Villalta, S., Fabris, F., Simioni, P., Sartori, M.T.

“…No data are available on rivaroxaban use in renal transplant recipients and on its surmised interaction with immunosuppressants. The aim was to investigate…”
Get full text

Cell Therapy for Parkinson's Disease: A Translational Approach to Assess the Role of Local and Systemic Immunosuppression by Aron Badin, R., Vadori, M., Vanhove, B., Nerriere‐Daguin, V., Naveilhan, P., Neveu, I., Jan, C., Lévèque, X., Venturi, E., Mermillod, P., Van Camp, N., Dollé, F., Guillermier, M., Denaro, L., Manara, R., Citton, V., Simioni, P., Zampieri, P., D'avella, D., Rubello, D., Fante, F., Boldrin, M., De Benedictis, G. M., Cavicchioli, L., Sgarabotto, D., Plebani, M., Stefani, A. L., Brachet, P., Blancho, G., Soulillou, J. P., Hantraye, P., Cozzi, E.

“…Neural transplantation is a promising therapeutic approach for neurodegenerative diseases; however, many patients receiving intracerebral fetal allografts…”
Get full text

Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma by CASTOLDI, E., SIMIONI, P., TORMENE, D., ROSING, J., HACKENG, T. M.

“…Background: Protein S and tissue factor pathway inhibitor (TFPI) act together in down‐regulating coagulation. Objective: To investigate the TFPI/protein S…”
Get full text

Taking care of inpatients with fragility hip fractures: the hip-padua osteosarcopenia (Hip-POS) fracture liaison service model by Arcidiacono, G P, Ceolin, C, Sella, S, Camozzi, V, Bertocco, A, Torres, M O, Rodà, M G, Cannito, M, Berizzi, A, Romanato, G, Venturin, A, Cianci, V, Pizziol, A, Pala, E, Cerchiaro, M, Savino, S, Tessarin, M, Simioni, P, Sergi, G, Ruggieri, P, Giannini, S

“…Osteoporotic fragility fractures (FF), particularly those affecting the hip, represent a major clinical and socio-economic concern. These fractures can lead to…”
Get full text

Clinical and laboratory characteristics of isolated lupus anticoagulants by Mattia, E., Tonello, M., Del Ross, T., Zerbinati, P., Campello, E., Simioni, P., Ruffatti, A.

“…•Currently the clinical significance of isolated-LAC is controversial.•Isolated LAC significantly prevailed in patients with disorders different from APS.•The…”
Get full text

Thromboelastometry for guiding bleeding management of the critically ill patient: a systematic review of the literature by Haas, T, Görlinger, K, Grassetto, A, Agostini, V, Simioni, P, Nardi, G, Ranucci, M

“…A systematic review of the published literature clearly demonstrates the usefulness of thromboelastometry (ROTEM®) in detecting coagulation disorders in severe…”
Get full text

“In vitro” correction of the severe factor V deficiency‐related coagulopathy by a novel plasma‐derived factor V concentrate by Bulato, C., Novembrino, C., Anzoletti, M. Boscolo, Spiezia, L., Gavasso, S., Berbenni, C., Tagariello, G., Farina, C., Nardini, I., Campello, E., Peyvandi, F., Simioni, P.

“…Introduction Severe congenital factor V (FV) deficiency is a rare bleeding disorder characterized by very low/undetectable levels of FV. Fresh frozen plasma is…”
Get full text

New functional assays to selectively quantify the activated protein C‐ and tissue factor pathway inhibitor‐cofactor activities of protein S in plasma by Alshaikh, N. A., Rosing, J., Thomassen, M. C. L. G. D., Castoldi, E., Simioni, P., Hackeng, T. M.

“…Essentials Protein S is a cofactor of activated protein C (APC) and tissue factor pathway inhibitor (TFPI). There are no assays to quantify separate APC and…”
Get full text

The haemostatic system in acromegaly: a single-centre case–control study by Campello, E., Marobin, M., Barbot, M., Radu, C. M., Voltan, G., Spiezia, L., Gavasso, S., Ceccato, F., Scaroni, C., Simioni, P.

“…Purpose Although the mortality from acromegaly is due in most cases to an increased cardiovascular risk, no study has globally evaluated the haemostatic…”
Get full text

Hemostatic Findings in Ascitic Fluid: A Cross‐Sectional Study in 70 Dogs by Zoia, A., Drigo, M., Piek, C.J., Simioni, P., Caldin, M.

“…Background Ascitic fluids of horses and humans have fibrinolytic activity, independent of the underlying mechanism of fluid formation. Objective To determine…”
Get full text

Influence of single nucleotide polymorphisms on thrombin generation in factor V Leiden heterozygotes by Segers, O, Simioni, P, Tormene, D, Castoldi, E

“…Carriership of the factor V (FV) Leiden mutation increases the risk of venous thromboembolism (VTE) ~4-fold, but the individual risk of each FV Leiden carrier…”
Get more information

Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency by Nuzzo, F., Bulato, C., Nielsen, B. I., Lee, K., Wielders, S. J., Simioni, P., Key, N. S., Castoldi, E.

“…Summary Coagulation factor V (FV) deficiency is a rare autosomal recessive bleeding disorder. We investigated a patient with severe FV deficiency (FV:C < 3%)…”
Get full text

“Hypocoagulable” thromboelastography profiles in patients with cyanotic congenital heart disease: Facts or technical artifacts? by Spiezia, L, Campello, E, Simioni, P

Get full text

Hyperfibrinolysis during liver transplantation detected by classical parameters and thromboelastometry by Maggiolo, S, Campello, E, Spiezia, L, Tredese, A, Saggiorato, G, Gavasso, S, Feltracco, P, Simioni, P

Get full text

Homozygous F5 deep‐intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet‐rich plasma by CASTOLDI, E., DUCKERS, C., RADU, C., SPIEZIA, L., ROSSETTO, V., TAGARIELLO, G., ROSING, J., SIMIONI, P.

“…Background: Coagulation factor (F) V deficiency is associated with a bleeding tendency of variable severity, but phenotype determinants are largely unknown…”
Get full text